Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Busulfan, Melphalan, and Escalating Carfilzomib in MM ASCT
NCT03795597Phase 2Unknown
- Sponsor
- Loyola University Chicago
- Start
- May 2019
- Primary completion
- Nov 2022
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in multiple myeloma (MM), sponsored by Loyola University Chicago. Status: unknown.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03795597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03795597.